Scientific publications

Phase II trial of image-based high-dose-rate interstitial brachytherapy for previously irradiated gynecologic cancer

Martínez-Monge R(1), Cambeiro M(2) [SP], Rodríguez-Ruiz ME(2), Olarte A(2), Ramos LI(2) [SP], Villafranca E(3), Bascón N(4), Jurado M(5).

(1) Department of Radiation Oncology, Clínica Universitaria de Navarra, University of Navarra, Pamplona, Navarre, Spain.
(2) Department of Radiation Oncology, Clínica Universitaria de Navarra, University of Navarra, Pamplona, Navarre, Spain.
(3) Department of Radiation Oncology, Hospital de Navarra, Pamplona, Navarre, Spain.
(4) Department of Radiation Oncology, Hospital Clínico Universitario, Zaragoza, Spain.
(5) Department of Gynaecology, University of Navarra, Pamplona, Navarre, Spain. 

Magazine: Brachytherapy

Date: May 30, 2014

Gynaecology and Obstetrics Radiation Oncology

PURPOSE:
To report the disease-free Grade ≥3 complication-free survival of a Phase II protocol of reirradiation with high-dose-rate (HDR) interstitial brachytherapy (ITB) in previously irradiated gynecologic cancer.

METHODS AND MATERIALS:
Fifteen patients with previously irradiated cervical (n = 6), endometrial (n = 6), and vulvovaginal tumors (n = 3) were treated with HDR-ITB alone to a median dose of 38 Gy in 8 b.i.d. fractions over 4 consecutive days. Prior treatments included surgery (n = 12; 80%), external irradiation (n = 15; 100%), and brachytherapy (n = 9; 60%). Average clinical target volume Size was 60.9 cc (range, 14.8-165.3 cc), and median time to reirradiation was 3.9 years (range, 0.4-22.7 years).

RESULTS:
With a median followup of 2.8 years (range, 1.2-9.2 years), 3 patients (20.0%) developed Grade ≥3 toxicity consisting of Grade 3 intestinal obstruction (n = 1), Grade 4 rectovesical fistula (n = 1), and Grade 5 intestinal obstruction (n = 1). Six patients remain alive and without evidence of disease at last followup. Two patients are alive with disease progression, and 7 patients have died, 4 of them from disease progression and 3 from other causes. The 2-year disease-free Grade ≥3 complication-free survival was 40%.

CONCLUSIONS:
HDR-ITB alone is a reasonable salvage treatment option in a significant number of patients with previously irradiated gynecologic tumors.

CITA DEL ARTÍCULO  Brachytherapy. 2014 May-Jun;13(3):219-24. doi: 10.1016/j.brachy.2014.01.008.

you maybe interested

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra